Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):211-219. doi: 10.6004/jnccn.2018.7095.

2.

What are the most promising new agents in myelodysplastic syndromes?

Chandhok NS, Boddu PC, Gore SD, Prebet T.

Curr Opin Hematol. 2019 Mar;26(2):77-87. doi: 10.1097/MOH.0000000000000483.

PMID:
30632987
3.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

Blood Adv. 2018 Oct 23;2(20):2681-2690. doi: 10.1182/bloodadvances.2018021436.

4.

Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.

Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ.

Cancer. 2018 Nov 1;124(21):4211-4220. doi: 10.1002/cncr.31688. Epub 2018 Sep 14.

PMID:
30216436
5.

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

Ball B, Komrokji RS, Ad├Ęs L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T.

Blood Adv. 2018 Aug 28;2(16):2063-2071. doi: 10.1182/bloodadvances.2018015529.

6.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

7.

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM.

Leuk Lymphoma. 2019 Jan;60(1):246-249. doi: 10.1080/10428194.2018.1468893. Epub 2018 Jul 2. No abstract available.

PMID:
29963936
8.

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD.

Blood Cancer J. 2018 Jun 11;8(6):55. doi: 10.1038/s41408-018-0081-8. No abstract available.

9.

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD.

Clin Cancer Res. 2018 Aug 1;24(15):3519-3527. doi: 10.1158/1078-0432.CCR-17-3763. Epub 2018 May 1.

PMID:
29716921
10.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.

Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121.

11.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219. [Epub ahead of print] No abstract available.

PMID:
29667455
12.

Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.

Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK.

Blood. 2018 May 24;131(21):2402-2405. doi: 10.1182/blood-2018-01-827881. Epub 2018 Apr 16. No abstract available.

PMID:
29661788
13.

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1754-1758. doi: 10.1016/j.bbmt.2018.03.025. Epub 2018 Apr 9.

PMID:
29649620
14.

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.

Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ.

Blood. 2018 Feb 15;131(7):818-821. doi: 10.1182/blood-2017-10-811729. Epub 2017 Dec 19. No abstract available.

15.

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Al Ali N, Fenaux P, Gore SD, Komrokji R.

Oncotarget. 2017 Jun 14;8(47):81926-81935. doi: 10.18632/oncotarget.18477. eCollection 2017 Oct 10.

16.

Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study.

Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ.

PLoS One. 2017 Sep 13;12(9):e0184747. doi: 10.1371/journal.pone.0184747. eCollection 2017.

17.

Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Norsworthy KJ, DeZern AE, Tsai HL, Hand WA, Varadhan R, Gore SD, Gojo I, Pratz K, Carraway HE, Showel M, McDevitt MA, Gladstone D, Ghiaur G, Prince G, Seung AH, Benani D, Levis MJ, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:25-32. doi: 10.1016/j.leukres.2017.08.009. Epub 2017 Aug 30. Review.

18.

US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box.

Zeidan AM, Gore SD, Davidoff AJ.

J Clin Oncol. 2017 Oct 1;35(28):3264. doi: 10.1200/JCO.2017.74.3104. Epub 2017 Aug 8. No abstract available.

PMID:
28787256
19.

Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life.

Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X.

J Clin Oncol. 2017 Oct 20;35(30):3417-3424. doi: 10.1200/JCO.2017.72.7149. Epub 2017 Aug 7.

20.

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD.

Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31. Review.

21.

Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.

Press KR, Uy N, Keefer J, Gore SD, Carraway HE, Sakoian S, Prebet T.

Leuk Lymphoma. 2018 Mar;59(3):755-757. doi: 10.1080/10428194.2017.1354373. Epub 2017 Jul 25. No abstract available.

PMID:
28738707
22.

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N.

J Natl Compr Canc Netw. 2017 Jul;15(7):926-957. doi: 10.6004/jnccn.2017.0116.

PMID:
28687581
23.

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.

Uy N, Singh A, Gore SD, Prebet T.

Expert Opin Pharmacother. 2017 Aug;18(12):1213-1224. doi: 10.1080/14656566.2017.1349100. Epub 2017 Aug 1. Review.

24.

Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.

Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF.

Cancer. 2017 Oct 1;123(19):3763-3771. doi: 10.1002/cncr.30818. Epub 2017 Jun 22.

25.

Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.

Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ.

Cancer. 2017 Oct 1;123(19):3754-3762. doi: 10.1002/cncr.30814. Epub 2017 Jun 16.

26.

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP.

J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9.

27.

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.

Prebet T, Toma A, Cluzeau T, Sekeres MA, Vey N, Park S, Al Ali N, Sugrue MM, Komrokji R, Fenaux P, Gore SD.

Oncotarget. 2017 Jun 6;8(23):37866-37874. doi: 10.18632/oncotarget.15200.

28.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

29.

Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.

Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM.

Transfusion. 2017 Feb;57(2):289-295. doi: 10.1111/trf.13934. Epub 2016 Nov 22.

30.

Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.

Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X.

Prostate. 2017 Apr;77(5):437-445. doi: 10.1002/pros.23281. Epub 2016 Nov 21.

31.

A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.

Zeidan AM, Smith BD, Carraway HE, Gojo I, DeZern A, Gore SD.

Br J Haematol. 2017 Jan;176(2):241-247. doi: 10.1111/bjh.14407. Epub 2016 Oct 28.

PMID:
27790720
32.

Selecting initial treatment of acute myeloid leukaemia in older adults.

Podoltsev NA, Stahl M, Zeidan AM, Gore SD.

Blood Rev. 2017 Mar;31(2):43-62. doi: 10.1016/j.blre.2016.09.005. Epub 2016 Oct 8. Review.

PMID:
27745715
33.

Epigenetics in Cancer: A Hematological Perspective.

Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T.

PLoS Genet. 2016 Oct 10;12(10):e1006193. doi: 10.1371/journal.pgen.1006193. eCollection 2016 Oct. Review.

34.

Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.

Ball B, Zeidan A, Gore SD, Prebet T.

Leuk Lymphoma. 2017 May;58(5):1022-1036. doi: 10.1080/10428194.2016.1228927. Epub 2016 Sep 21. Review.

35.

Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.

Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD.

Br J Haematol. 2016 Dec;175(5):829-840. doi: 10.1111/bjh.14305. Epub 2016 Sep 21.

PMID:
27650975
36.

Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.

Norsworthy KJ, Cho E, Arora J, Kowalski J, Tsai HL, Warlick E, Showel M, Pratz KW, Sutherland LA, Gore SD, Ferguson A, Sakoian S, Greer J, Espinoza-Delgado I, Jones RJ, Matsui WH, Smith BD.

Leuk Res. 2016 Oct;49:90-7. doi: 10.1016/j.leukres.2016.09.003. Epub 2016 Sep 3.

PMID:
27619199
37.

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.

Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X.

Leuk Lymphoma. 2017 Apr;58(4):982-985. doi: 10.1080/10428194.2016.1214954. Epub 2016 Aug 25. No abstract available.

PMID:
27558206
38.

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE.

Clin Cancer Res. 2017 Feb 15;23(4):899-907. doi: 10.1158/1078-0432.CCR-16-1274. Epub 2016 Aug 22.

39.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

40.

Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.

Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM.

Ann Hematol. 2016 Oct;95(11):1895-8. doi: 10.1007/s00277-016-2761-4. Epub 2016 Jul 29. No abstract available.

PMID:
27468851
41.

DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.

Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, Suarez L, Gore SD, Delwel R, Paietta E, Tallman MS, Fernandez H, Melnick A, Le Beau MM, Kogan S, Salomonis N, Figueroa ME, Grimes HL.

Cancer Discov. 2016 May;6(5):501-15. doi: 10.1158/2159-8290.CD-16-0008. Epub 2016 Mar 25.

42.

Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.

Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X.

Cancer. 2016 May 15;122(10):1598-607. doi: 10.1002/cncr.29945. Epub 2016 Mar 11.

43.

Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database.

Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA.

Cancer. 2016 Apr 15;122(8):1209-15. doi: 10.1002/cncr.29913. Epub 2016 Feb 23.

44.

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.

Stahl M, Gore SD, Vey N, Prebet T.

Expert Opin Investig Drugs. 2016;25(3):307-17. doi: 10.1517/13543784.2016.1146251. Review.

PMID:
26807602
45.

Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.

Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Figueroa M, Gabrilove J, Erba HP, Tallman MS, Litzow M, Gore SD; Eastern Cooperative Oncology Group and North American Leukemia intergroup.

Br J Haematol. 2016 Feb;172(3):384-91. doi: 10.1111/bjh.13832. Epub 2015 Nov 18.

46.

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

Laille E, Shi T, Garcia-Manero G, Cogle CR, Gore SD, Hetzer J, Kumar K, Skikne B, MacBeth KJ.

PLoS One. 2015 Aug 21;10(8):e0135520. doi: 10.1371/journal.pone.0135520. eCollection 2015.

47.

Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ.

J Comp Eff Res. 2015 Aug;4(4):327-40. doi: 10.2217/cer.15.20.

48.

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Nazha A, Sekeres MA, Gore SD, Zeidan AM.

Oncologist. 2015 Sep;20(9):1069-76. doi: 10.1634/theoncologist.2015-0067. Epub 2015 Jul 20. Review.

49.

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.

Lee EJ, Podoltsev N, Gore SD, Zeidan AM.

Blood Rev. 2016 Jan;30(1):1-10. doi: 10.1016/j.blre.2015.06.004. Epub 2015 Jun 19. Review.

PMID:
26119927
50.

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.

Kim TK, Gore SD, Zeidan AM.

Semin Hematol. 2015 Jul;52(3):172-83. doi: 10.1053/j.seminhematol.2015.04.003. Epub 2015 Apr 8. Review.

Supplemental Content

Loading ...
Support Center